Astellas Considers Options To Shed All Or Parts Of Diabetes Unit Prosidion
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas is weighing its options for metabolic subsidiary Prosidion, likely divesting all or part of it, as the company continues its integration, and shedding, of OSI Pharmaceuticals. If it sells off Prosidion, Astellas will be left with few pipeline entries in the diabetes space
You may also be interested in...
AstraZeneca Strengthens Diabetes R&D With Option On Astellas/Prosidion's Early-Stage Compounds
AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.
AstraZeneca Strengthens Diabetes R&D With Option On Prosidion's Early-Stage Compounds
AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.
Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets
TOKYO - Unlike its top rival Takeda Pharmaceuticals Co. Ltd., Astellas Pharma Inc. says it will primarily look for organic growth in emerging markets, although the Japanese major is not adverse to M&A if it finds the right opportunity